Compare Stocks: ENLV, XLO, EXOZ, and IMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$0.81 +10.9%	$2.27	$0.64 ▼ $27.15	$14.10M	1.42	295,895 shs	349,945 shs
EXOZ eXoZymes	$6.43 +3.9%	$6.00	$4.35 ▼ $18.40	$59.73M	3.14	5,472 shs	16,335 shs
IMA ImageneBio	$4.89 -2.6%	$5.47	$3.94 ▼ $9.10	$55.51M	0.7	15,216 shs	77,052 shs
XLO Xilio Therapeutics	$9.13 +1.0%	$9.03	$6.47 ▼ $12.74	$60.08M	-0.14	9,395 shs	22,937 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	0.00%	-15.94%	-46.23%	-91.35%	-94.88%
EXOZ eXoZymes	0.00%	-2.58%	-8.66%	-17.88%	-52.79%
IMA ImageneBio	0.00%	-3.74%	-12.83%	-18.50%	-41.44%
XLO Xilio Therapeutics	0.00%	+2.24%	-1.08%	+3.87%	-13.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$0.81 +10.9%	$2.27	$0.64 ▼ $27.15	$14.10M	1.42	295,895 shs	349,945 shs
EXOZ eXoZymes	$6.43 +3.9%	$6.00	$4.35 ▼ $18.40	$59.73M	3.14	5,472 shs	16,335 shs
IMA ImageneBio	$4.89 -2.6%	$5.47	$3.94 ▼ $9.10	$55.51M	0.7	15,216 shs	77,052 shs
XLO Xilio Therapeutics	$9.13 +1.0%	$9.03	$6.47 ▼ $12.74	$60.08M	-0.14	9,395 shs	22,937 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	0.00%	-15.94%	-46.23%	-91.35%	-94.88%
EXOZ eXoZymes	0.00%	-2.58%	-8.66%	-17.88%	-52.79%
IMA ImageneBio	0.00%	-3.74%	-12.83%	-18.50%	-41.44%
XLO Xilio Therapeutics	0.00%	+2.24%	-1.08%	+3.87%	-13.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	30,584.35% Upside
EXOZ eXoZymes	1.00	Sell	N/A	N/A
IMA ImageneBio	2.20	Hold	$29.00	493.05% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENLV, XLO, EXOZ, and IMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
EXOZ eXoZymes	$70K	852.43	N/A	N/A	$0.40 per share	16.08
IMA ImageneBio	$800K	69.38	N/A	N/A	$11.91 per share	0.41
XLO Xilio Therapeutics	$43.77M	1.37	N/A	N/A	$7.31 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	9/25/2026 (Estimated)
EXOZ eXoZymes	-$9.16M	-$1.19	N/A	N/A	N/A	N/A	-292.15%	-158.66%	N/A
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest ENLV, XLO, EXOZ, and IMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	EXOZ eXoZymes	N/A	-$0.33	N/A	-$0.33	N/A	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	193.24	193.24
EXOZ eXoZymes	0.01	3.81	3.81
IMA ImageneBio	N/A	21.47	21.47
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
EXOZ eXoZymes	N/A
IMA ImageneBio	75.00%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
EXOZ eXoZymes	72.41%
IMA ImageneBio	2.22%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	34	17.49 million	15.34 million	Optionable
EXOZ eXoZymes	32	9.28 million	2.56 million	N/A
IMA ImageneBio	18	11.35 million	11.10 million	Not Optionable
XLO Xilio Therapeutics	76	6.58 million	6.09 million	Not Optionable

ENLV, XLO, EXOZ, and IMA Headlines

Recent News About These Companies

Reviewing Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL)

3 hours ago | americanbankingnews.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

August 28, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

April 1, 2026 | zacks.com

Xilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56

March 28, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, XLO, EXOZ, and IMA Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$0.81 +0.08 (+10.92%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$0.81 0.00 (-0.07%)

As of 09/18/2026 07:59 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

eXoZymes NASDAQ:EXOZ

$6.43 +0.24 (+3.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.47 +0.04 (+0.56%)

As of 09/18/2026 06:34 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

ImageneBio NASDAQ:IMA

$4.89 -0.13 (-2.59%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.82 -0.07 (-1.53%)

As of 09/18/2026 04:10 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Xilio Therapeutics NASDAQ:XLO

$9.13 +0.09 (+1.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.16 +0.03 (+0.38%)

As of 09/18/2026 04:10 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, XLO, EXOZ, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, XLO, EXOZ, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, XLO, EXOZ, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, XLO, EXOZ, and IMA Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

eXoZymes NASDAQ:EXOZ

ImageneBio NASDAQ:IMA

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, XLO, EXOZ, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, XLO, EXOZ, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, XLO, EXOZ, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, XLO, EXOZ, and IMA Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

eXoZymes NASDAQ:EXOZ

ImageneBio NASDAQ:IMA

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools